Smoked cannabis for chronic neuropathic pain: A randomized controlled trial

CMAJ. Canadian Medical Association Journal

Volumn 182, Issue 14, 2010, Pages

  Ware, Mark A ^a   Wang, Tongtong ^a   Shapiro, Stan ^a   Robinson, Ann ^c   Ducruet, Thierry ^c   Huynh, Thao ^a   Gamsa, Ann ^b   Bennett, Gary J ^b   Collet, Jean Paul ^d  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c Boreal Primum   (Canada)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; CANNABIS; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; PLACEBO; TETRAHYDROCANNABINOL; DRONABINOL;

ADULT; AGED; ARTICLE; BURNING SENSATION; CANNABIS SMOKING; CHRONIC PAIN; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; DRY EYE; FEMALE; HEADACHE; HUMAN; MALE; MOOD; NEUROPATHIC PAIN; OUTCOME ASSESSMENT; PAIN ASSESSMENT; PARESTHESIA; POSTOPERATIVE PAIN; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SLEEP; TREATMENT OUTCOME; CHRONIC DISEASE; CROSSOVER PROCEDURE; DRUG EFFECTS; MIDDLE AGED; NEURALGIA; PAIN MEASUREMENT; STATISTICAL MODEL;

ADULT; AGED; CHRONIC DISEASE; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRONABINOL; FEMALE; HUMANS; LINEAR MODELS; MALE; MARIJUANA SMOKING; MIDDLE AGED; NEURALGIA; PAIN MEASUREMENT; PLACEBOS; QUALITY OF LIFE; SLEEP; TREATMENT OUTCOME;

EID: 77958035149     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: 10.1503/cmaj.091414     Document Type: Article

References (33)

1. Berger A, Dukes EM, Oster G. Clinical characteristics and economic costs of patients with painful neuropathic disorders. J Pain 2004;5:143-9. (Pubitemid 38879392)
2. Mendell JR, Sahenk Z. Clinical practice. Painful sensory neuropathy. N Engl J Med 2003;348:1243-55.
3. Moulin DE, Clark AJ, Gilron I, et al. Pharmacological management of chronic neuropathic pain - consensus statement and guidelines from the Canadian Pain Society. Pain Res Manag 2007;12:13-21.
4. Attal N, Cruccu G, Haanpaa M, et al. EFNS guidelines on pharmacological treatment of neuropathic pain. Eur J Neurol 2006;13:1153-69.
5. Mechoulam R. The pharmacohistory of Cannabis sativa. In: Mechoulam R, editors. Cannabinoids as therapeutic agents. Boca Raton (FL): CRC Press; 1986. p. 1-19.
6. Meng ID, Manning BH, Martin WJ, et al. An analgesia circuit activated by cannabinoids. Nature 1998;395:381-3.
7. Ware MA, Gamsa A, Persson J, et al. Cannabis for chronic pain: case series and implications for clinicians. Pain Res Manag 2002;7:95-9.
8. Svendsen KB, Jensen TS, Bach FW. Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial. BMJ 2004;329:253.
9. Rog DJ, Nurmikko TJ, Friede T, et al. Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology 2005;65:812-9. (Pubitemid 41362120)
10. Nurmikko TJ, Serpell MG, Hoggart B, et al. Sativex successfully treats neuropathic pain characterised by allodynia: a randomised, double-blind, placebo-controlled clinical trial. Pain 2007;133:210-20.
11. Blake DR, Robson P, Ho M, et al. Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis. Rheumatology (Oxford) 2005;45:50-2.
12. Skrabek RQ, Galimova L, Ethans K, et al. Nabilone for the treatment of pain in fibromyalgia. J Pain 2008;9:164-73.
13. Ware MA, Doyle CR, Woods R, et al. Cannabis use for chronic non-cancer pain: results of a prospective survey. Pain 2003;102:211-6.
14. Clark AJ, Ware MA, Yazer E, et al. Patterns of cannabis use among patients with multiple sclerosis. Neurology 2004;62:2098-100.
15. Abrams DI, Jay CA, Shade SB, et al. Cannabis in painful HIV-associated sensory neuropathy: a randomized placebo-controlled trial. Neurology 2007;68:515-21.
16. Ellis RJ, Toperoff W, Vaida F, et al. Smoked medicinal cannabis for neuropathic pain in HIV: a randomized, crossover clinical trial. Neuropsychopharmacology 2009;34:672-80.
17. Wilsey B, Marcotte T, Tsodikov A, et al. A randomized, placebo-controlled, crossover trial of cannabis cigarettes in neuropathic pain. J Pain 2008;9:506-21.
18. Dworkin RH, Turk DC, Farrar JT, et al. Core outcome measures for chronic pain clinical trials: IMMPACT recommendations. Pain 2005;113:9-19.
19. Melzack R. The short-form McGill Pain Questionnaire. Pain 1987;30:191-7.
20. Parrott AC, Hindmarch I. The Leeds Sleep Evaluation Questionnaire in psychopharmacological investigations - a review. Psychopharmacology (Berl) 1980;71:173-9.
21. Shacham S. A shortened version of the Profile of Mood States. J Pers Assess 1983;47:305-6.
22. Hurst NP, Kind P, Ruta D, et al. Measuring health-related quality of life in rheumatoid arthritis: validity, responsiveness and reliability of EuroQol (EQ-5D). Br J Rheumatol 1997;36:551-9. (Pubitemid 27344490)
23. Chait LD, Burke KA. Preference for high- versus low-potency marijuana. Pharmacol Biochem Behav 1994;49:643-7.
24. Chait LD, Evans SM, Grant KA, et al. Discriminative stimulus and subjective effects of smoked marijuana in humans. Psychopharmacology (Berl) 1988;94:206-12.
25. Chait LD, Zacny JP. Reinforcing and subjective effects of oral delta 9-THC and smoked marijuana in humans. Psychopharmacology (Berl) 1992;107:255-62.
26. Dworkin RH, Turk DC, Wyrwich KW, et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain 2008;9:105-21.
27. Good Clinical Practice: Consolidated Guidelines. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. E6(R1):1996; Switzerland. Available at: www.ich.org/cache/compo/ 276-254-1.html (accessed 2010 Aug. 18).
28. Backonja M, Beydoun A, Edwards KR, et al. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. JAMA 1998;280:1831-6.
29. Richter RW, Portenoy R, Sharma U, et al. Relief of painful diabetic peripheral neuropathy with pregabalin: a randomized, placebo-controlled trial. J Pain 2005;6:253-60.
30. Azorlosa JL, Heishman SJ, Stitzer ML, et al. Marijuana smoking: effect of varying delta 9-tetrahydrocannabinol content and number of puffs. J Pharmacol Exp Ther 1992;261:114-22.
31. Grotenhermen F. Pharmacokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokinet 2003;42:327-60.
32. Abrams DI, Vizoso HP, Shade SB, et al. Vaporization as a smokeless cannabis delivery system: a pilot study. Clin Pharmacol Ther 2007;82:572-8.
33. Zuurman L, Roy C, Schoemaker RC, et al. Effect of intrapulmonary tetrahydrocannabinol administration in humans. J Psychopharmacol 2008;22:707-16.